OpenResearchAlpha

eJHaem · 16 Nov 2026

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

Steven M. Bair, John C. Byrd, Jonathan Gutman, Mitchell Phelps, Amy J. Johnson, Bita Fakhri, Kerry A. Rogers, Jennifer A. Woyach, Michael R. Grever, Manali Kamdar, Steven E. Coutre, Daniel A. Pollyea

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
27
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. Methods In this multicenter, phase 1, 3+3 dose‐escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28‐day ibrutinib run‐in (420 mg daily), then added lenalidomide with intra‐patient escalation to a cohort‐assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Results Twenty‐seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow‐up of 50.4 months, median progression‐free survival was 69.5 months (95% CI 53.4–NE). Conclusion Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. Trial Registration ClinicalTrials.gov identifier: NCT01886859

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (12)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (27)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 7 more references

A free account opens the rest of the citing papers and references on every paper’s page.

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia - QAI OpenResearch